The crystal structure of SOTI-III in complex with bovine pancreatic trypsin has been solved to 1.7 Ǻ resolution.
Introduction
Proteases and their natural inhibitors play key roles in biochemical and physiological processes. They are involved in protein digestion, defense mechanisms of plants, degradation of misfolded proteins and turnover, signalling, enzyme activation, regulation, and many other processes (Antao & Malcata, 2005; Ehrmann & Clausen, 2004) . Based on the reaction mechanism proteases are basically categorized into serine, cysteine, aspartic and metalloproteases. Protease activity has to be tightly controlled and two basic regulatory mechanisms have been described: production of inactive precursors (Khan & James, 1998) and active inhibition by proteins, peptides or non-proteinaceous compounds (Clardy et al., 2006; Krowarsch et al., 2003) . For the latter mechanism the inhibitor blocks the active site of the proteolytic enzyme.
Serine protease inhibitors (SPIs) are classified based on their mode of inhibition either as canonical, non-canonical inhibitors or serpins (Krowarsch et al., 2003; Otlewski et al., 1999) . Serpins form an irreversible covalent enzyme-inhibitor complex, causing large conformational changes of the enzyme and thus disrupting the active site (Stubbs et al., 1990; Silverman et al., 2001) . In contrast the noncanonical inhibitors, such as hirudin, bind with their N-terminus via two interaction regions (Huntington & Carrell, 2001 ). This results in a two-step kinetic, mainly due to a substrate-mimic in the active site and an additional exosite binding on the surface of the protease (Farady et al., 2008) .
Canonical inhibitors with a size of 3-21 kDa per domain obstruct the active site with a single convex inhibitor loop without causing conformational changes (Bode & Huber, 2000) . The SPIs P 1 residue is essential for complex formation and has substantial influence on the association energy (Lu et al., 1993) .
From a structural point of view, there are various types of serine protease inhibitors such as α-helical proteins, β-sheet proteins, α/β-proteins and small disulfide rich proteins with different folds. While the serpin superfamily shares a highly ordered α 1 -antitrypsin motif (Huber & Carrell, 1989; Loebermann et al., 1984) the non-canonical SPIs have no well-defined structural motif. However, they share a disordered N-terminal region that forms a parallel β-sheet with the protease upon complex formation (Otlewski et al., 1999) . Some canonical serine protease inhibitors, such as the BPTI, Kazal, potato, cereal, SSI, STI or the ecotin family have typical secondary structure elements and a conserved hydrophobic core. Others such as squash, Bowman-Birk, grasshopper and Ascaris lack this hydrophobic core, but maintain a defined tertiary structure, which is mainly formed and stabilized by intramolecular disulfide bonds (Krowarsch et al., 2003; Bateman & James, 2011) .
Among those, members of the cystine-knot miniprotein or knottin family show extraordinary chemical, thermal and proteolytic stability due to their unique disulfide linkage (Kolmar, 2009; Heitz et al., 2008; Werle et al., 2008) . Knottins are broadly distributed in nature and can be isolated from various organisms like arthropoda, mollusca, porifera, vertebrata, fungi and plants (Kolmar, 2009) .
They act as ion-channel blockers (Williams et al., 2008) , protease inhibitors (Avrutina et al., 2005) , have insecticidal (Jennings et al., 2001) , antimicrobial (Tam et al., 1999 ), anti-HIV (Gustafson et al., 2004 or hemolytic activity (Daly et al., 1999) . Several studies showed that the loop length as well as residue composition could be modified as long as the cysteine pattern is preserved (Avrutina et al., 2005; Kimura et al., 2011; Sommerhoff et al., 2010) . Due to their small size, their long-term stability and their likely oral availability, they are promising candidates for diagnostic and therapeutic applications (Kolmar, 2010; Werle et al., 2008; Kimura et al., 2011) .
In 2007 a new family of serine protease inhibitors with a knottin-like disulfide bridge connectivity of CysI -CysIV, CysII -CysV and CysIII -CysVI has been described (Kowalska et al., 2007) . Based on their unique sequence and the C-terminal location of the inhibitor loop those SPIs were proposed to form the new Mirabilis SPI family (Figure 1 ; http://knottin.cbs.cnrs.fr/). Unfortunately, no subsequent new publication with additional information or more detailed description of this family has been reported so far.
Here we report the first multi-milligram solid phase synthesis of SOTI-III and a F14A mutant. The folded mini-proteins were utilized for structural elucidation in complex with pancreatic trypsin and kinetic analysis.
Materials and Methods

Synthesis of linear precursors and oxidative folding
Peptides were assembled on Fmoc-Gln preloaded TentaGel resin (Rapp Polymere) using standard 
RP-HPLC and LC-MS analysis
Analytical RP-HPLC was performed with a Varian LC 920 system equipped with a Phenomenex Synergi 4µ Hydro-RP 80 Å (250 x 4.6 mm, 4 µm) column (see appendix) at a flow rate of 1 mL/min.
Semi-preparative RP-HPLC was performed with a Varian LC 940 system equipped with an axiapacked Phenomenex Luna C18 (250 x 21.2 mm, 5 µm, 100 Å) column using linear acetonitrile gradients (Appendix A) with a flow rate of 18 mL/min. LC-MS was performed with a Shimadzu LC-MS 2020 equipped with a Phenomenex Jupiter C4 (50 x 1 mm, 5 µm, 300 Å) column using linear acetonitrile gradients with a flow rate of 0.2 mL/min (Appendix B).
Crystallization and data collection
Trypsin from bovine pancreas (Sigma-Aldrich) was dissolved in 1 mM HCl (pH 2.0) and 10 mM CaCl 2 . Protein was purified on a Superdex 75 16/60 column (GE Healthcare) in 25 mM MES pH 5.5, 50 mM NaCl and 10 mM CaCl 2 at 277 K and concentrated to 12 mg/mL. Prior to crystallization set up lyophilized SOTI-III was added to 12 mg/mL trypsin (in 25 mM MES pH 5.5, 50 mM NaCl and 10 mM CaCl 2 ) to a final concentration of 2.5 mM and kept on ice for 30 min. alignments were prepared using PyMOL (Schrodinger, 2010) . Data and refinement statistics are summarized in Table 1 .
Enzymatic methods
Bovine pancreatic trypsin (Sigma-Aldrich) was active-site titrated (Chase & Shaw, 1967; Jameson et al., 1973) using 4-methylumbelliferyl guanidinobenzoate (MUGB; 1µM; Sigma-Aldrich) in reaction buffer (50 mM Tris/HCl, 150 mM NaCl, 0.01% (v/v) Triton X-100, 0.01% (w/v) sodium azide, pH 7.6).
The concentration of inhibitory active SOTI was determined assuming a 1:1 interaction of enzyme and inhibitor (Avrutina et al., 2005; Pohlig et al., 1996) . Several inhibitor concentrations (0.05 -1.5 µM) were incubated with trypsin (0.2 µM) for 30 min at room temperature. Subsequently, the residual activity was quantified over 5 min by monitoring the relative fluorescence of the hydrolyzed carbobenzoxy-L-arginine-7-amino-4-methylcoumarin (75 µM; Sigma-Aldrich). The reactions were carried out in 96-well microtiter plates (Greiner Bion-One, flat bottom, black) and were monitored in a Tecan Genios reader (ex. 360 nm, em. 465 nm). The normalized reaction rates were fitted using equation (1), with unfixed E 0 . The ratio of active sites (see above) and the fitted E 0 gives a correction factor for the active inhibitor concentration.
To determine the inhibition constants the reaction velocity was monitored after 30 min pre-incubation of enzyme and inhibitor. The substrate hydrolysis of Boc-QAR-pNA (250 µM, Bachem) was analyzed over a period of 30 min at 405 nm (Tecan Genios). The apparent inhibition constant (K i app )
was calculated by fitting (Sigmaplot 11, Marquard-Levenberg algorithm) the relative reaction velocities using the Morrison equation (1) (Morrison, 1969) .
All measurements were carried out in triplicate. The substrate independent inhibition constants (K i )
were calculated from K i app and K m of the enzyme using equation (2). The Michaelis Menten constant K m for the substrate and trypsin was determined previously (Tischler et al., 2012) .
Results and Discussion
SPPS & oxidative folding
SOTI-III and the F14A variant were synthesized by microwave-assisted solid phase peptide synthesis.
The purity of the linear precursors was verified by HPLC ( Figure 2 ) and LC-ESI-MS analysis ( Figure   S1 ). Oxidative folding of the crude peptide was conducted in an aqueous buffer system and monitored by analytical HPLC (Figure 2 ) and LC-ESI-MS ( Figure S1 ). After the final semi-preparative HPLC purification a total yield of 23.8 % and 16.2 % for SOTI-III and the F14A variant respectively was obtained
Structural studies
Co-complex crystals of purified SOTI-III with bovine pancreatic trypsin had P2 1 symmetry and diffracted to 1.7 Å. The structure shows additional F o -F c electron density for the inhibitor covering the active site of trypsin ( Figure S2 ). The asymmetric unit is packed with three trypsin molecules, each blocked by the inhibitor (Figure 3a) . SOTI-III secondary structure shows the proposed C4 -C21, C11
-C25 and C20 -C36 disulfide linkage (Figure 3b and 4a (Kowalska et al., 2007) ). While the first cysteine bridge shapes a right handed hook, the second and last one forms a right and left handed spiral, respectively (Table S1 ). The inhibitor overall structure is mainly constructed by β-turns ( Figure   4 and Table S2 ). The turns are interrupted by disulfide bonds, three short anti-parallel β-strands (residues 9-11, 26-28 and 33-36) and a short four amino acid long helix (residues 16-19). The inhibitor loop (residues 26-34), which contains the S 1 site filling Arg32 (P 1 residue), forms a β-hairpin with a γ-turn ( Figure 3c and 4, Table S2b ).
SOTI-III coordinates at the active site of each trypsin molecule without causing major dislocation of protease loops. Here the averaged RMS with 0.227±0.026 Å of all three trypsin/inhibitor complexes in the asymmetric unit (ASU) is in the same range as the RMS of each trypsin/inhibitor complex when compared with apo-trypsin (RMS = 0.259±0.008 Å) ( Figure S3 ). SOTI-III is most flexible in region of loop 1, loop 3 and a three-residue helix as seen in a B-factor putty of all three monomers ( Figure   S4 ).
On average 15 residues of the inhibitor (~750 Å 2 ) interact with 24 residues of trypsin covering ~980 Å 2 of the protease surface (Table S3 ). In total 12 hydrogen bonds are involved in coordination of the inhibitor. Notably, the P 1 residue Arg32 forms eight of these interacting H-bonds ( Figure S5 ).
Phe14 of SOTI-III binds to a cleft apart from the active site, which is formed by Ile78, Trp144 and Pro155 of trypsin (Figure 3d ). Interestingly, a detailed search in the Protein Data bank showed that this cleft is not addressed by other trypsin inhibitors ( Figure 5 , appendix D).
To investigate the role of Phe14 upon trypsin binding and inhibition a F14A variant of SOTI-III was synthesized and co-crystallized. The co-complex with the SOTI-III F14A, which crystallized in the same P2 1 space group, shows that in monomer C of trypsin the residual space, which was formerly filled by the side chain of Phe14 (Figure 3d ), is partly occupied by the protease residue Tyr154
( Figure S6 ). In one of the remaining two monomers the electron density is rather weak for the Tyr154 side chains, suggesting that the side chain might swap between those two rotamers.
The K i of SOTI-III wild type and of the F14A variant were determined as described in materials and methods. They were found to inhibit trypsin in the nanomolar range. The substrate independent inhibition constants for SOTI-III and for SOTI-III F14A were calculated from respective inhibition curves (Figure 2c ) with 60.9 ± 8.4 and 201.8 ± 27.7 nM, respectively. This indicates that Phe14 contributes to trypsin binding. However, the main inhibitory effect is mediated by the C-terminal inhibitor loop. This is supported by the fact that more than half of the inhibitor coordinating H-bonds are formed by Arg32 within this loop region. This is not surprising, since other P 1 residues were also reported to contribute strongly to inhibitor binding (Krowarsch et al., 2005) .
Comparison studies with other trypsin inhibitors
The structure of SOTI-III was previously modeled in silico (http://knottin.cbs.cnrs.fr/). Although the calculated structure is close to that of the co-crystallization with trypsin, significant conformational differences in the C-terminal inhibitory loop region (residues 25 -35) are present. The average RMSD of the superposed structure is 2.33 Å with the largest RMS deviation of over 8 Å in the inhibitor loop region ( Figure S7 ).
SOTI-III exhibits the unique, but well-defined pseudo-knot motif, which is typical for the members of the "knottin" family ( Figure 3b, Figure 4 ). This structural element determines the stability and rigidity, similar to the majority of known canonical protease inhibitors (squash, Bowman-Birk, grasshopper, hirustasin, chelonianin, and Ascaris) that lack a hydrophobic core and extensive secondary structure. It contains a canonical inhibitor loop located at the C-terminus thereby defining it as a member of the huge family of canonical serine protease inhibitors.
The C-terminal location of the inhibitor loop is a unique feature of SOTI-III. Due to the amino acid sequence, the additional interaction of Phe14 and the location of the inhibitor loop we support the notion of Kowalska (Kowalska et al., 2007) that SOTI-III together with other Mirabilis and Spinacea serine proteinase inhibitors form a new family of inhibitors. 
